This review examines the evidence underpinning the development of BMP-based agonists and inhibition of activin/GDF signaling as transformative therapeutics for pulmonary arterial hypertension.
This review highlights emerging therapeutic approaches targeting BMP and activin/GDF signaling pathways to potentially reverse established pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is an often fatal condition, the primary pathology of which involves loss of pulmonary vascular perfusion due to progressive aberrant vessel remodeling. The reduced capacity of the pulmonary circulation places increasing strain on the right ventricle of the heart, leading to death by heart failure. Currently, licensed therapies are primarily vasodilators, which have increased the median post-diagnosis life expectancy from 2.8 to 7 years. Although this represents a substantial improvement, the search continues for transformative therapeutics that reverse established disease. The genetics of human PAH heavily implicates reduced endothelial bone morphogenetic protein (BMP) signaling as a causal role for the disease pathobiology. Recent approaches have focused on directly enhancing BMP signaling or removing the inhibitory influence of pathways that repress BMP signaling. In this critical commentary, we review the evidence underpinning the development of two approaches: BMP-based agonists and inhibition of activin/GDF signaling. We also address the key considerations and questions that remain regarding these approaches.
Upton et al. (Mon,) conducted a review in Pulmonary arterial hypertension. BMP-based agonists and inhibition of activin/GDF signaling was evaluated. This review examines the evidence underpinning the development of BMP-based agonists and inhibition of activin/GDF signaling as transformative therapeutics for pulmonary arterial hypertension.